Table 4.
Factors associated with overall survival in subgroup patients with multiple CRLM.
| Comparison | Univariate analyses | Stepwise multivariate analyses | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age (years) | ≥60 vs. <60 | 0.592 (0.291–1.202) | 0.147 | ||
| Gender | Male vs. Female | 1.151 (0.563–2.352) | 0.701 | ||
| BMI (kg/m2) | ≥25 vs. <25 | 1.373 (0.672–2.806) | 0.384 | ||
| DM | Yes vs. No | 1.078 (0.515–2.258) | 0.842 | ||
| Sarcopenia | Yes vs. No | 3.322 (1.585–6.993) | 0.002 | 3.571 (1.508–8.403) | 0.004 |
| Synchronous | Yes vs. No | 1.866 (0.755–4.610) | 0.177 | ||
| Neoadjuvant chemotherapy | Yes vs. No | 1.226 (0.589–2.551) | 0.585 | ||
| Adjuvant chemotherapy | Yes vs. No | 0.298 (0.088–1.008) | 0.051 | ||
| Blood loss (cc) | ≥300 vs. <300 | 1.940 (0.956–3.936) | 0.067 | ||
| CEA (ng/ml) | ≥ 10 vs. <10 | 1.627 (0.808–3.273) | 0.173 | ||
| Primary tumor site | right vs. left | 1.699 (0.645–4.475) | 0.283 | ||
| Tumor stage | T3,4 vs. 2,1 | 1.147 (0.348–3.787) | 0.821 | ||
| Nodal status | N2 vs. N0, 1 | 1.124 (0.536–2.353) | 0.757 | ||
| Main tumor (cm) | >3 vs. ≤3 | 1.822 (0.865–3.836) | 0.114 | ||
| AST (U/L) | per 1 U/L increase | 1.000 (0.979–1.021) | 0.966 | ||
| ALT (U/L) | per 1 U/L increase | 0.998 (0.982–1.014) | 0.776 | ||
| Albumin (g/dl) | per 1 g/dl increase | 0.356 (0.115–1.098) | 0.072 | ||
| Platelet (103/μL) | per 103/μL increase | 1.002 (0.997–1.008) | 0.353 | ||
| NLR | > 3 vs. ≤3 | 1.234 (0.563–2.703) | 0.599 | ||
Abbreviation: CRLM, colorectal liver metastasis; HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; CEA, carcinoembryonic antigen; aspartate aminotransferase; ALT, alanine aminotransferase; NLR, neutrophil-to-lymphocyte ratio.